Company Overview

ZYUS Life Sciences Corporation is a Canadian life sciences company operating at the intersection of pharmaceutical drug delivery technology and the regulated cannabis industry. The company focuses on developing non-combustible, precision-dosed cannabinoid products using proprietary delivery platforms designed to improve bioavailability, dosing accuracy, and patient experience. Its activities primarily fall within the medical cannabis, pharmaceutical development, and biotechnology-enabled consumer health industries.

The company’s core revenue strategy is centered on intellectual property–driven drug delivery systems rather than traditional cannabis cultivation. ZYUS Life Sciences was founded in 2014 and later became publicly listed on the TSX Venture Exchange under the ticker ZYUS.V. Over time, the company evolved from a vertically integrated cannabis model into a technology-focused organization emphasizing pharmaceutical-grade formulation and delivery, positioning itself as a differentiated player within the medical cannabis and cannabinoid therapeutics market.

Business Operations

ZYUS Life Sciences’ operations are organized around the development and commercialization of proprietary drug delivery technologies for cannabinoids, particularly sublingual and transdermal formats. Its primary business units include ZYUS Life Sciences Drug Delivery Platforms, which encompass orally dissolvable tablets, films, and transdermal systems designed to deliver cannabinoids without smoking or vaping. Revenue generation has historically been limited, with the company primarily operating in a development and early commercialization stage.

The company operates under Canadian federal cannabis regulations and maintains partnerships with licensed manufacturers to support formulation, testing, and potential commercialization. ZYUS does not rely on large-scale cultivation assets, instead leveraging formulation know-how, patents, and licensing arrangements. International operations remain limited, with most activities concentrated in Canada. Public disclosures indicate no material revenue concentration from foreign jurisdictions as of the most recent filings.

Strategic Position & Investments

Strategically, ZYUS Life Sciences positions itself as a platform technology company within the cannabinoid and pharmaceutical delivery space. Its growth initiatives focus on advancing proprietary technologies through clinical validation, intellectual property protection, and potential licensing or co-development agreements with pharmaceutical or consumer health partners. The company has emphasized its intent to align cannabinoid products with pharmaceutical standards, differentiating from recreational cannabis competitors.

Notable investments have been directed toward research and development, patent filings, and regulatory compliance infrastructure rather than acquisitions of operating cannabis businesses. As of publicly available disclosures, ZYUS has not completed any transformational acquisitions, and information regarding material portfolio subsidiaries beyond ZYUS Life Sciences Corporation remains limited. Data inconclusive based on available public sources regarding late-stage clinical trials or commercial licensing agreements.

Geographic Footprint

ZYUS Life Sciences is headquartered in Canada, with its principal corporate presence in Saskatchewan. The company’s operational footprint is primarily domestic, reflecting Canada’s federally regulated medical cannabis framework and established pathways for cannabinoid research and commercialization.

While ZYUS has indicated interest in addressing international medical cannabis and pharmaceutical markets, particularly in North America and select global life sciences jurisdictions, there is limited verified evidence of active foreign subsidiaries or revenue-generating international operations. International influence is currently indirect, primarily through intellectual property strategy rather than physical operations abroad.

Leadership & Governance

ZYUS Life Sciences is led by a management team with backgrounds spanning life sciences, cannabis regulation, and pharmaceutical development. Leadership has emphasized a strategy centered on science-first product development, regulatory compliance, and long-term intellectual property value creation. The company operates under governance standards applicable to TSX Venture Exchange–listed issuers.

Key executives include:

• Brent Zettl – Chief Executive Officer
• Brent Zettl – President
• Data inconclusive based on available public sources – Other executive officer roles, including Chief Financial Officer and Chief Operating Officer, have been disclosed inconsistently across public filings and announcements, and current appointments could not be independently verified across multiple sources without conflict.